Deepanshi Dhar
Overview
Explore the profile of Deepanshi Dhar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dhar D, Raina K, Kumar D, Wempe M, Bagby S, Pitts T, et al.
Mol Carcinog
. 2020 Aug;
59(10):1227-1240.
PMID: 32816368
Chemoresistance to gemcitabine (GEM)-a frontline chemotherapeutic, resulting from its dysfunctional uptake and metabolism in cancer cells, is a major contributing factor for failed therapy in pancreatic cancer (PanC) patients. Therefore,...
2.
Dhar D, Raina K, Kant R, Wempe M, Serkova N, Agarwal C, et al.
Carcinogenesis
. 2019 Jun;
40(9):1164-1176.
PMID: 31194859
The established role of bitter melon juice (BMJ), a natural product, in activating master metabolic regulator adenosine monophosphate-activated protein kinase in pancreatic cancer (PanC) cells served as a basis for...
3.
da Silva R, Dhar D, Raina K, Kumar D, Kant R, Cagnon V, et al.
Sci Rep
. 2018 Jun;
8(1):9540.
PMID: 29934570
Prostate cancer (PCa) is the most common malignancy and second leading cause of cancer-related deaths in American men. Proliferating cells have higher need for nutrients and oxygen, triggering angiogenesis that...
4.
Dhar D, Deep G, Kumar S, Wempe M, Raina K, Agarwal C, et al.
Mol Carcinog
. 2018 May;
57(9):1166-1180.
PMID: 29727019
Pancreatic cancer (PanC) is one of the deadliest malignancies worldwide and frontline treatment with gemcitabine becomes eventually ineffective due to increasing PanC resistance, suggesting additional approaches are needed to manage...
5.
Dhar D, Raina K, Agarwal R
Curr Med Chem
. 2017 Mar;
25(22):2545-2565.
PMID: 28322154
Background: Pancreatic cancer management remains a major challenge to society. Poor prognosis results in dismal patient survival rates and quality of life post chemo/radiation therapies. Although progress has been made...
6.
Rigby C, Roy S, Deep G, Guillermo-Lagae R, Jain A, Dhar D, et al.
Carcinogenesis
. 2016 Oct;
38(1):40-50.
PMID: 27729375
Non-melanoma skin cancers (NMSC) are a growing problem given that solar ultraviolet B (UVB) radiation exposure is increasing most likely due to depletion of the atmospheric ozone layer and lack...
7.
Raina K, Kumar S, Dhar D, Agarwal R
J Biomed Res
. 2016 Aug;
30(6):452-465.
PMID: 27476880
Globally, the risk of colorectal cancer (CRC) as well as the incidence of mortality associated with CRC is increasing. Thus, it is imperative that we look at alternative approaches involving...
8.
Deep G, Kumar R, Jain A, Dhar D, Panigrahi G, Hussain A, et al.
Sci Rep
. 2016 Mar;
6:23135.
PMID: 26979487
Prostate cancer (PCa) is the leading malignancy among men. Importantly, this disease is mostly diagnosed at early stages offering a unique chemoprevention opportunity. Therefore, there is an urgent need to...
9.
Goswami D, Tewari-Singh N, Dhar D, Kumar D, Agarwal C, Ammar D, et al.
Cornea
. 2015 Nov;
35(2):257-66.
PMID: 26555588
Purpose: To evaluate the toxic effects and associated mechanisms in corneal tissue exposed to the vesicating agent, nitrogen mustard (NM), a bifunctional alkylating analog of the chemical warfare agent sulfur...
10.
Schlaepfer I, Nambiar D, Ramteke A, Kumar R, Dhar D, Agarwal C, et al.
Oncotarget
. 2015 Jun;
6(26):22836-56.
PMID: 26087400
Hypoxia is an independent prognostic indicator of poor outcome in several malignancies. However, precise mechanism through which hypoxia promotes disease aggressiveness is still unclear. Here, we report that under hypoxia...